RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Wayne W. Harding to Dopamine Agonists

This is a "connection" page, showing publications Wayne W. Harding has written about Dopamine Agonists.
Connection Strength

1.525
  1. Giri R, Alberts I, Harding WW. Synthesis, pharmacological evaluations, and molecular docking studies on a new 1,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine framework: Rigidification of D1 receptor selective 1-phenylbenzazepines and discovery of a new 5-HT6 receptor scaffold. Chem Biol Drug Des. 2020 08; 96(2):825-835.
    View in: PubMed
    Score: 0.747
  2. Karki A, Juarez R, Namballa HK, Alberts I, Harding WW. Identification of C10 nitrogen-containing aporphines with dopamine D1 versus D5 receptor selectivity. Bioorg Med Chem Lett. 2020 04 15; 30(8):127053.
    View in: PubMed
    Score: 0.738
  3. Manuszak M, Harding W, Gadhiya S, Ranaldi R. (-)-Stepholidine reduces cue-induced reinstatement of cocaine seeking and cocaine self-administration in rats. Drug Alcohol Depend. 2018 08 01; 189:49-54.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support